BCR and mixed phenotype acute leukemia: We recruited 17 BCR::ABL1-positive MPAL patients; 15 received TKI combined with induction chemotherapy: 8 with imatinib, 4 with dasatinib, 2 with orebatinib, and 1 with flumatinib.